Dr. Corinne Summers, MD
Claim this profileSeattle Children's Hospital
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Lymphoma
2 reported clinical trials
2 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
CD22 positive
CD33 positive
2Lymphoma
CD22 positive
Affiliated Hospitals
Clinical Trials Corinne Summers, MD is currently running
CAR T-Cell Therapy
for Leukemia and Lymphoma
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR). The CAR used in this study can recognize CD22, a protein expressed on the surface of leukemia and lymphoma cells. The phase 1 part of this study will determine the safety and appropriate dose level of these CAR T cells, and the phase 2 part of the study will determine how effective this CAR T cell therapy is. Both patients who have never had prior CAR T cell therapy and those who have had prior CAR T cell therapy may be eligible to participate in this study.
Recruiting1 award Phase 1 & 215 criteria
CD33 CART Therapy
for Acute Myeloid Leukemia
This phase 1/2 trial aims to determine the safety and feasibility of antiCD33 chimeric antigen receptor (CAR) expressing T cells (CD33CART) in children and adolescents/young adults (AYAs) with relapsed/refractory acute myeloid leukemia (AML). The trial will be done in two phases: Phase 1 will determine the maximum tolerated dose of CD33CART cells using a 3+3 trial design, with dose-escalation for autologous products separated from dose-escalation for an allogeneic arm. Phase 2 is an expansion phase designed to evaluate the rate of response to CD33CART.
Recruiting1 award Phase 1 & 219 criteria
More about Corinne Summers, MD
Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Corinne Summers, MD has experience with
- SCRI-CAR22v2
- CD33CART
Breakdown of trials Corinne Summers, MD has run
T-Lymphoblastic Leukemia/Lymphoma
Acute Myeloid Leukemia
Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Corinne Summers, MD specialize in?
Corinne Summers, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Lymphoma. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved CD22 positive patients, or patients who are CD33 positive.
Is Corinne Summers, MD currently recruiting for clinical trials?
Yes, Corinne Summers, MD is currently recruiting for 2 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Corinne Summers, MD has studied deeply?
Yes, Corinne Summers, MD has studied treatments such as SCRI-CAR22v2, CD33CART.
What is the best way to schedule an appointment with Corinne Summers, MD?
Apply for one of the trials that Corinne Summers, MD is conducting.
What is the office address of Corinne Summers, MD?
The office of Corinne Summers, MD is located at: Seattle Children's Hospital, Seattle, Washington 98105 United States. This is the address for their practice at the Seattle Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.